Abstract 929P
Background
The incidence of Laryngeal Squamous Cell Carcinoma (LSCC) has increased over the past 30 years, presenting new challenges in the management of this disease. In response to these evolving needs, we developed a machine learning (ML) prognostic model to optimize the treatment strategies for patients diagnosed with advanced LSCC.
Methods
Data from 2000 to 2020 were obtained from the SEER database. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test was used to compare variables. The Kaplan-Meier estimator, log-rank test, and Cox regression analysis identified prognostic factors for overall survival (OS) and cancer-specific survival (CSS). We constructed prognostic models using ML algorithms to predict 5-year survival. The data were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
A total of 7,350 patients were included: 2,689 with glottic (GC), 4,349 with supraglottic (SuGC), and 312 with subglottic (SG) cancers. The median patient age was 60 years. A total of 88.8% of the patients had a T3 and T4. The largest racial group was white, comprising 74.8% of the cases, and 21.1% of the cases were black. Most cases were stage IV AJCC (89.5%), and 41.4% of the patients had N2. Of the patients, 52% underwent total laryngectomy, which was the most common surgical procedure (39.1%). ML was used to identify the most important features of GC, including age, sex, and AJCC staging. Age and sex were considered as key factors for SuGC metastasis. For SC, the most important features identified were surgery combined with radiotherapy, sex, and surgery combined with chemoradiotherapy.
Conclusions
This study presents ML models tailored to three anatomical sites of LSCC. Key factors such as age and sex for GC and SuGC and treatment combinations for SG. These models underscore their utility in personalized medicine, enabling clinicians to customize treatment strategies based on individual characteristics and improve clinical outcomes.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1015P - The efficacy and mechanism of pan-FGFR inhibitor (AZD4547) combined with immunoagonists or immunosuppressants in FGFR-positive tumors
Presenter: Qizhi Ma
Session: Poster session 03
1016P - Phase I study of SOF10 plus atezolizumab in patients with advanced/recurrent solid tumours
Presenter: Toshihiko Doi
Session: Poster session 03
1017P - Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Presenter: Samuel Klempner
Session: Poster session 03
1018P - Leveraging innate and adaptive immunity with AFM24 and atezolizumab in metastatic gastric cancer
Presenter: Omar Saavedra Santa Gadea
Session: Poster session 03
1019P - Bispecific PD1-IL2 antibody reshapes the inhibitory immune microenvironment of SMARCA4 mutant non-small cell lung cancer by reversing CD8+T cell exhaustion
Presenter: Bo Cheng
Session: Poster session 03
Resources:
Abstract
1020P - Highly potent and specific bivalent T cell engager (TCE) targeting PRAME on HLA-A*02:01
Presenter: Athanasia Dasargyri
Session: Poster session 03
1021P - Chemotherapy and hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC
Presenter: Adel Benlahrech
Session: Poster session 03
1022P - A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Jonathan Riess
Session: Poster session 03
1023P - Long-term follow up of patients treated with a DNA vaccine (pTVG-HP) for PSA-recurrent prostate cancer
Presenter: Douglas McNeel
Session: Poster session 03
1024P - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster session 03